Merck Sues To Block Sandoz's Generic Zetia

Law360, New York (October 2, 2012, 7:53 PM EDT) -- Units of Merck & Co. Inc. on Thursday hit generics maker Sandoz Inc. with a patent infringement suit in New Jersey federal court in their latest effort to block generic versions of the anti-cholesterol drug Zetia.

Merck claims that Sandoz's generic version of Zetia, known chemically as ezetimibe, infringes four of its patents — U.S. Patent Numbers RE 42,461, 5,846,966, 7,030,106 and 7,612,058. The patents expire between 2014 and 2022, according to the complaint.

Sandoz notified Merck on Aug. 15 that it had submitted an Abbreviated...
To view the full article, register now.